Why Excluding Amgen Could Shake Up Baron Health Care Fund’s Portfolio Performance
Baron Health Care Fund’s decision to sidestep Amgen isn’t just a quirky deviation — it’s a bet against the mainstream. Most healthcare funds treat Amgen as a staple, given its $140 billion market cap and entrenched position in biotech. Baron’s move signals a willingness to challenge sector orthodoxy, putting conviction above convention. According to Yahoo Finance, this omission is a rare stance, especially when Amgen’s stock has delivered steady returns and forms a core holding in rivals’ portfolios.
The rationale? Baron’s managers have cited concerns over Amgen’s growth trajectory and pipeline risk. Amgen’s late-stage assets — like its biosimilars and immunology drugs — face patent cliffs and regulatory hurdles. For Baron, the payout from avoiding stagnation outweighs the comfort of holding a blue-chip. But this exposes the fund to volatility. By skipping Amgen, Baron forfeits a defensive anchor that cushions downturns — a role Amgen played during the 2022 biotech rout, when its shares fell just 7% versus a 22% dive in the S&P Biotech ETF.
This strategy contrasts sharply with peer funds. The Fidelity Select Health Care Portfolio, for example, holds Amgen as a top-three position, banking on its dividend reliability and scale. Baron’s exclusion is a double-edged sword: it frees capital for high-growth bets, but risks missing out if Amgen surprises to the upside or stabilizes sector losses. Investors should watch closely — this isn’t just a stock pick, it’s a statement about what healthcare funds should be.
Quantifying the Impact: Data-Driven Insights into Fund Performance Without Amgen
The numbers tell a nuanced story. In the 12 months since Baron dropped Amgen, the fund posted a 9.2% return, trailing the Health Care Select Sector SPDR ETF (XLV) at 11.7% and lagging the Fidelity fund at 12.3%. Amgen’s own stock delivered a 10.5% gain in the same period, buoyed by strong earnings and resilient demand for legacy products. Baron’s portfolio, meanwhile, tilted toward smaller, faster-growing names — Moderna, Vertex, and Intuitive Surgical — that amplified both upside and drawdown.
Volatility has ticked up. Baron’s annualized standard deviation climbed to 18.1% from 15.8% pre-omission, compared to XLV’s 13.9%. The fund’s Sharpe ratio fell from 0.85 to 0.73, underscoring the trade-off: more risk, less reward. The absence of Amgen’s stabilizing cash flows and dividend (currently yielding 3.1%) means Baron is more vulnerable to biotech sell-offs.
Peer comparison is instructive. The Janus Henderson Global Life Sciences Fund, which kept Amgen as a top holding, saw smaller drawdowns during the Q1 2024 sector correction — losing 4% versus Baron’s 6.2%. Amgen’s defensive posture, backed by $6.6 billion in annual free cash flow, insulated funds from rate hikes and drug pricing headlines.
Sector exposure has shifted. Baron’s biotech allocation rose from 36% to 43%, while pharmaceuticals dipped from 27% to 21%. This tilt boosts growth potential, but leaves the fund exposed if large-cap pharma outperforms. The data is clear: omitting Amgen has cost Baron a measure of stability and return, but the longer-term payoff will depend on whether its riskier bets deliver outsized gains.
Diverse Stakeholder Perspectives on Amgen’s Exclusion from a Leading Healthcare Fund
Baron’s managers defend the move as a disciplined call. They argue Amgen’s growth is capped, citing flat sales in flagship drugs and a lack of blockbuster launches. Their view: better to own innovators than incumbents. Healthcare analysts are split. Some see this as prudent — Amgen’s biologics face biosimilar threats, and regulatory scrutiny is rising. Others warn that skipping Amgen is risky; it’s still a cash machine with a proven track record of weathering market storms.
Investors are reacting with a mix of skepticism and curiosity. Baron’s longtime holders worry about volatility and missed dividend income, but others appreciate the fund’s willingness to chase alpha over comfort. Institutional allocators have not yet dumped Baron, but inflows slowed by 8% in Q1 2024 — a sign that risk tolerance is being tested.
Amgen itself shrugs off the omission. The company points to its 12% EPS growth in 2023 and a robust pipeline — including obesity drugs and next-gen biosimilars. Amgen’s IR team frames fund exclusions as cyclical, noting that large funds often rotate exposure based on macro or regulatory shifts.
Patients and providers aren’t directly affected by fund decisions, but capital flows inform R&D budgets and drug access over time. If Baron’s shift toward smaller biotechs pays off, it could channel more investment into novel therapies. If not, the sector risks starving established players of support, potentially slowing innovation.
Tracing the Evolution: How Historical Fund Allocations to Amgen Have Influenced Healthcare Investment Trends
Baron’s relationship with Amgen is cyclical. From 2015 to 2019, Amgen was a steady 4-6% slice of Baron’s portfolio, anchoring returns during sector turbulence. In 2016, when biotech crashed 18%, Baron’s Amgen allocation cushioned losses, allowing the fund to outperform peers by 2.1%. But as Amgen’s pipeline matured and growth slowed, Baron gradually trimmed exposure — first dropping to 2% in 2020, then zero by late 2022.
Most healthcare funds have taken the opposite approach. The Vanguard Health Care Fund has consistently kept Amgen in its top-10, citing dividend stability. During the COVID-19 pandemic, Amgen’s antibody research was seen as a hedge against riskier biotech — a safe harbor when smaller names cratered.
Amgen’s historical performance has shaped sector allocations. After its 2014-2018 run, when shares surged 52% on back-to-back drug approvals, fund managers doubled down on large-cap biotech. But the 2019-2021 plateau — with revenue growth stuck at 4% — prompted some funds, like Baron, to pivot toward disruptors.
The lesson: funds that overweighted Amgen enjoyed stability but sometimes missed out on explosive growth from smaller biotech names. Those that ditched Amgen early bore sharper swings, but occasionally snagged outsized returns. Baron’s latest move is less about Amgen itself, and more about shifting the fund’s DNA from defensive to aggressive.
Implications for Investors: What the Amgen Omission Signals for Healthcare Fund Strategies
For Baron Health Care Fund investors, the message is clear: expect more volatility and less income. Amgen’s exclusion signals a pivot toward risk, favoring early-stage and mid-cap biotechs over established giants. Investors who prize stability and dividends may need to reconsider their allocations — Baron’s yield has dipped to 0.4%, compared to XLV’s 1.5% and Fidelity’s 1.2%.
Sector exposure has become more concentrated. Baron now holds 43% in biotech, 21% in pharma, and 18% in medical devices — a tilt that magnifies both upside and downside. This risks underperformance if large-cap pharma rebounds or if regulatory headwinds slam smaller biotechs.
The fund’s risk profile has shifted. Volatility is up 14%, and the maximum drawdown in Q1 2024 reached 6.2%. Investors should brace for wider performance swings, especially during FDA cycle news or patent disputes.
Portfolio guidance: those seeking stability should diversify with funds that hold Amgen or other large-cap biotechs. Aggressive investors may stick with Baron, betting that its riskier picks will outperform over a 3-5 year horizon. But the omission of Amgen is a warning: healthcare funds are no longer one-size-fits-all, and sector rotation can upend expected returns.
Forecasting the Future: How Amgen’s Role in Healthcare Funds Could Evolve Amid Market Dynamics
Amgen’s exclusion won’t last forever — but its reintegration hinges on both company execution and broader sector shifts. If Amgen lands approval for its obesity drug or expands biosimilar revenues, funds like Baron may be forced to revisit the decision. Historically, funds return to large-cap biotechs after major pipeline wins; Amgen’s 2014-2018 resurgence saw inflows spike 22% across sector ETFs.
Biotech investing is changing. New funds are prioritizing genomics, cell therapies, and AI-driven drug discovery — areas where Amgen is a late adopter. If the company pivots aggressively, it could recapture fund manager attention. But if it remains a slow-and-steady dividend payer, it risks being sidelined by funds chasing innovation.
Regulatory dynamics loom large. Medicare price negotiation and FDA reform could squeeze margins for established players, favoring nimble biotechs. But if pricing headwinds ease or biosimilar adoption accelerates, Amgen’s cash flow could regain its defensive appeal.
The most likely scenario: Baron and similar funds will continue to exclude Amgen until its growth trajectory changes or sector volatility spikes. If smaller biotechs stumble or macro risk rises, Amgen’s role as a stabilizer will become attractive again. For investors, monitor FDA approvals, regulatory shifts, and fund flows — the next allocation pivot will be driven by headlines, not legacy.
⚠️ Disclaimer: This article is for informational purposes only and does not constitute financial advice. Always do your own research before making investment decisions.
The Bottom Line
- Baron's omission of Amgen highlights the risk and reward of diverging from sector norms.
- The fund's performance lags peers who hold Amgen, raising questions about its strategy.
- Investors must weigh conviction-driven investing against the stability offered by blue-chip stocks.
